Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00928694 | Fenofibrate Bioequivalence Study (0767-031) | PHASE1 | COMPLETED | 14 | — | — | Feb 1, 2003 | Apr 1, 2004 | Aug 19, 2015 | - | — |
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Fenofibrate U.S. Formulation |
| 2 | ACTIVE_COMPARATOR | Fenofibrate UK Formulation |
| Name | Type | Description |
|---|---|---|
| fenofibrate (U.S. formulation) | DRUG | Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods. |
| fenofibrate (UK formulation) | DRUG | Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods. |
Inclusion Criteria: * Subject is in good health * Subject is willing to follow all study guidelines Exclusion Criteria: * Subject has uncontrolled high blood pressure, impaired glucose tolerance, diabetes, or other major diseases or chronic conditions that would confound the results of the study ...